奥马珠单抗治疗儿童及青少年过敏性哮喘的系统评价  

Treatment of Omalizumabon Allergic Asthma in Children and Adolescents:A Systematic Review

作　　者：王亚芹 樊鹏利[1] 吕品[1] 陈博雅 李坤[1] 马培志[1] WANG Ya-qin;FAN Peng-li;LV Pin;CHEN Bo-ya;LI Kun;MA Pei-zhi(Department of Pharmacy,Henan Provincial People′s Hospital,Henan Zhengzhou 450003,China)

机构地区：[1]河南省人民医院药学部,河南郑州450003

出　　处：《中国药物评价》2021年第2期111-114,共4页Chinese Journal of Drug Evaluation

基　　金：国家自然科学基金81803357(新型PIM/AKT双重抑制剂的设计合成及抗前列腺癌活性研究);中国药学会科技开发中心科普项目(CMEI2020KPYJ00610)。

摘　　要：目的:对奥马珠单抗用于儿童及青少年过敏性哮喘的临床研究进行系统评价和Meta分析。方法:通过检索Pubmed、Medline和中国知网等数据库文献,截止日期为2020年6月21日。由2人进行文献筛选、资料提取以及质量评价,利用Rev Man5.3进行Meta分析。结果:共纳入4篇随机对照研究,包含1678例受试者。奥马珠单抗组哮喘恶化的风险较安慰剂组显著降低[RR=0.63,95%CI:(0.56,0.71),Z=7.37,P<0.00001],奥马珠单抗组哮喘治疗效果评级为优秀和良好的比例高于安慰剂组。奥马珠单抗治疗组不良反应和严重不良反应发生率均较低。结论:奥马珠单抗可显著降低儿童及青少年患者的哮喘重度恶化率,提高患者生活质量,且耐受性较好。Objective:To conduct a systematic review about the treatment of omalizumab on allergic asthma in children and adolescents.Methods:The databases including Pubmed,Medline and China National Knowledge Internet were searched by computer and deadline was June 21,2020.Two investigators screened studies,extracted data and evaluated quality of literatures,and Meta-analyses was conducted by Rev Man 5.3.Results:Four randomized controlled trials involved in 1678 subjects were included.Compared with placebo,the rate of asthma exacerbation was significantly reduced in patients treated with omalizumab[RR=0.63,95%CI:(0.56,0.71),Z=7.37,P<0.00001].The proportion of patients,who’s therapeutic effects were excellent or good when treated with omalizumab,was higher than those with placebo.The numbers of adverse reactions and severe adverse reactions with omalizumab were low.Conclusion:Omalizumab reduced rate of asthma exacerbation in children and adolescents,improved patients’quality of life and was well tolerated.

关 键 词：奥马珠单抗 过敏性哮喘 Ig E抗体 META分析 哮喘重度恶化 

分 类 号：R191[医药卫生—卫生事业管理] R725.6[医药卫生—公共卫生与预防医学]